Gilead Sciences
From open-encyclopedia.com - the free encyclopedia.
From the corporate Web Page:
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases worldwide. The company has seven commercially available products and focuses its research and clinical programs on anti-infectives. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
- Common stock is traded on The Nasdaq Stock Market under the symbol GILD
- Joined Nasdaq 100 in Q3 2001
- Highlights from fiscal year 2003
GAAP NON-GAAP Total Revenues $867.7 million $867.7 million Net Product Sales $836.3 million $836.3 million Total Expenses $913.8 million $428.3 million Net Income ($72.0) million $302.8 million EPS ($0.36) per diluted share $1.41 per diluted share Cash and Equivalents $707.0 million $707.0 million Stock Split (2-for-1) March 2002 Employees Approximately 1,500
Executive Committee
The Gilead Executive Committee provides guidance on strategy, business development, sales and marketing, and research and development. Its members include:
- John C. Martin, PhD, President and Chief Executive Officer
- Norbert W. Bischofberger, PhD, Executive Vice President, Research and Development
- John F. Milligan, PhD, Executive Vice President and Chief Financial Officer
- Anthony D. Caracciolo, Senior Vice President, Manufacturing
- Michael K. Inouye, Senior Vice President, Commercial Operations
- William A. Lee, PhD, Senior Vice President, Research
- John J. Toole, MD, PhD, Senior Vice President, Clinical Research
- Gregg H. Alton, Vice President and General Counsel
- Marsha Roberts, Vice President, Human Resources
Gilead Worldwide Gilead maintains research, development or manufacturing facilities in the United States and Europe. In the United States, operations are based in Foster City and San Dimas, California and Durham, North Carolina. European operations are based in Cambridge, United Kingdom; Dublin, Ireland and Paris, France. Additionally, sales and marketing organizations are located in the following cities: Athens, Greece; Cambridge, United Kingdom; Lisbon, Portugal; Madrid, Spain; Melbourne, Australia; Milan, Italy; Munich, Germany and Paris, France.
Product Portfolio
Gilead has seven products on the market, all tackling potentially life-threatening infectious diseases. Currently 9in 2004) the portfolio includes:
- Truvada (emtricitabine and tenofovir disoproxil fumarate)
- VireadŽ (tenofovir disoproxil fumarate)
- EmtrivaŽ (emtricitabine)
- AmBisomeŽ (amphotericin B) liposome for injection
- HepseraŽ (adefovir dipivoxil)
- TamifluŽ (oseltamivir phosphate)
- VistideŽ (cidofovir injection)
